妇科肿瘤实践中早期药物研发和免疫治疗计划安全实施的实用指南。
A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.
机构信息
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
出版信息
Gynecol Oncol. 2018 Nov;151(2):374-380. doi: 10.1016/j.ygyno.2018.08.037. Epub 2018 Sep 10.
The success of targeted and immune therapies in other malignancies has led to an exponential increase in the number of active and pending clinical trials using these therapeutic approaches in patients with gynecologic cancers. These novel investigational agents are associated with unique and potentially life-threatening toxicities and many require special multidisciplinary logistical considerations. The objective of this review is to describe a practical approach for the safe implementation of targeted and immune therapies in academic gynecologic oncology practices based on our experience at M.D. Anderson Cancer Center.
靶向治疗和免疫疗法在其他恶性肿瘤中的成功，促使越来越多的针对妇科癌症患者的临床试验采用这些治疗方法。这些新型的研究性药物与独特的、潜在危及生命的毒性相关，许多药物需要特殊的多学科后勤考虑。本综述的目的是基于我们在 M.D.安德森癌症中心的经验，描述一种在学术妇科肿瘤学实践中安全实施靶向治疗和免疫治疗的实用方法。
Zotero 插件